A study of abrupt phentermine cessation in patients in a weight management program

American Journal of Therapeutics

Volumn 18, Issue 4, 2011, Pages 292-299

  Hendricks, Ed J ^a   Greenway, Frank L ^b  

^a Center for Weight Management   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

addiction; addiction scale; obesity; obesity treatment; phentermine

Indexed keywords

AMPHETAMINE; CARBOHYDRATE; PHENTERMINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG EFFECT; DRUG WITHDRAWAL; HEALTH PROGRAM; HUMAN; HYPERPHAGIA; HYPERSOMNIA; INSOMNIA; IRRITABILITY; OBESITY; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SUBSTANCE ABUSE; SUICIDE; SYMPTOM; TENSION; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ADULT; APPETITE DEPRESSANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PHENTERMINE; QUESTIONNAIRES; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT REFUSAL; WITHHOLDING TREATMENT;

EID: 79960543395     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181d070d7     Document Type: Article

References (31)

1. Nathanson MH. The central action of beta-aminopropylbenzine (Benzadrine) clinical observations. J Am Med Assoc. 1937;108:528-531.
2. Ulrich H. Narcolepsy and its treatment with Benzedrine sulfate. N Engl JMed. 1937;217:696-701.
3. Lesses M, Myerson A. Human autonomic pharmacology XVI. Benzedrine sulfate as an aid in the treatment of obesity. N Engl J Med. 1938;218:119-124.
4. Ersner JS. The treatment of obesity due to dietary indiscretion (over-eating) with benzedrine sulfate. Endo-crinology. 1940;27:776-780.
5. Kalb SW. The effect of amphetamine (Benzedrine) sulfate and thyroid hormone in the treatment of obesity: observations on 500 cases. J Med Soc NJ. 1942;39:74-75.
6. Harris SC, Ivy AC, Searle LM. The mechanism of amphetamine-induced loss of weight. J Am Med Assoc. 1947;134:1468-1475.
7. Albrecht FK. The use of Benzedrine sulfate in obesity. Ann Intern Med. 1944;21:983-989.
8. Steel JM, Munro JF, Duncan LJP. A comparative trial of different regimens of fenfluramine and phentermine in obesity. The Practitioner. 1973;211:232-236.
9. Rossum JMV, Simon F. Locomotor activity and anorex-igenic action. Psychopharmacologia. 1969;14:248-254.
10. Griffiths RR, Winger G, Brady JV, et al. Comparison of behavior maintained by infusions of eight phenylethyl-amines in baboons. Psychopharmacology (Berl). 1976;50: 251-258.
11. Wojnicki FHE, Rothman RB, Rice KC, et al. Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food and cocaine presentation in the rhesus monkey. J Pharmacol Exp Ther. 1999;288: 550-560. (Pubitemid 29119664)
12. Jain NC, Budd RD, Sneath TC. Frequency of use or abuse of amphetamine-related drugs. Am J Drug Alcohol Abuse. 1979;6:53-57. (Pubitemid 10202063)
13. Kampman KM, Volpicelli JR, McGinnis DE, et al. Reliabi-lity and validity of the Cocaine Selective Severity Assessment. Addictive Behaviors. 1998;23:449-461. (Pubitemid 28311333)
14. McGregor C. Amphetamine Withdrawal: Nature, Time Course, and Treatment. PhD thesis. Adelaide: University of Adelaide; 2005.
15. McGregor C, Srisurapanont M, Jittiwutikarn J, et al. The nature, time course and severity of methamphet-amine withdrawal. Addiction (Abingdon, England). 2005; 100:1320-1329. (Pubitemid 41248073)
16. McGregor C, Srisurapanont M, Mitchell A, et al. Psycho-metric evaluation of the Amphetamine Cessation Symp-tom Assessment. J Subst Abuse Treat. 2008;34:443-449. (Pubitemid 351609289)
17. Hendricks EJ, Greenway FL, Westman EC, et al. A survey of prescribing practices of medical bariatricians. Obesity. 2008;16:S292-S293.
18. Pagoto SL, Curtin C, Lemon SC, et al. Association between adult attention deficit/hyperactivity disorder and obesity in the US population. Obesity. 2009;17: 539-544.
19. Ahmadi J, Kampman K, Dackis C. Outcome predictors in cocaine dependence treatment trials. Am J Addict. 2006;15: 434-439. (Pubitemid 46018039)
20. Ahmadi J, Kampman K, Dackis C, et al. Cocaine withdrawal symptoms identify 'Type B' cocaine-depen-dent patients. Am J Addict. 2008;17:60-64. (Pubitemid 351156991)
21. Ahmadi J, Kampman KM, Oslin DM, et al. Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment. Am J Addict. 2009;18:81-86.
22. Heinz AJ, Epstein DH, Schroeder JR, et al. Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat. 2006;31:355-364. (Pubitemid 44648651)
23. Topp L, Darke S. The applicability of the dependence syndrome to amphetamine. Drug Alcohol Depend. 1997;48: 113-118. (Pubitemid 27466471)
24. Shoptaw SJ, Kao U, Heinzerling K, et al. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev. 2009:CD003021.
25. Evans SM, Cone EJ, Henningfield JE. Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and sub-jective effects. J Pharmacol Exp Ther. 1996;279:1345-1356. (Pubitemid 27166783)
26. Wilens TE. Attention Deficit Hyperactivity Disorder and Substance Use Disorders. Am J Psychiatry. 2006;163: 2059-2063. (Pubitemid 46114223)
27. Wilens TE, Adamson J, Monuteaux MC, et al. Effect of prior stimulant treatment for attention-deficit/hyperac-tivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008;162:916-921.
28. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179-185. (Pubitemid 36071051)
29. Wilens TE, Monuteaux MC, Snyder LE, et al. The clinical dilemma of using medications in substance-abusing ado-lescents and adults with attention-deficit/hyperactivity disorder: what does the literature tell us? J Child Adolesc Psychopharmacol. 2005;15:787-798. (Pubitemid 41567150)
30. Frank A. The long-term management of obesity with continuing pharmacotherapy Obes Res. 2004;12: 1821-1827. (Pubitemid 41133032)
31. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev. 1999;20:805-875. (Pubitemid 30647075)